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Dr G. Chad Hughes (Durham, NC). I would like to thank the
Association for the opportunity to discuss this work and congratu-
late Joe on a great presentation. Joe and Alberto, great work. I just
have a few questions.
Although the authors state their initial experience has led them
to use this technique more widely, it was used in only 26% of the
242 patients undergoing Debakey type I dissection repair during
this time interval. This indicates the presence of bias with regard
to patient selection, surgeon preference, or both. Please describe
in more detail how patients are selected to undergo this procedure
because it would appear that the vast majority still do not receive
this adjunctive antegrade stent graft repair.
Dr Bavaria. That is a very fair question. That gets into the
methods of selection a little bit, and there was a little bit of an evo-
lution—especially in the really early phases.
The first 6 we did were actually done for significant malperfu-
sion problems, and when we looked at them—this was presented at
the Annual Meeting of The American Association for Thoracic
Surgery in 2006—we saw that we had very good remodeling.
This was the impetus for the entire effort. The fact of the matter948 The Journal of Thoracic and Cardiovascular Surgis, in our institution there are 5 aortic surgeons who take dissection
call; 2 of them do the procedure and 3 of them do not. So that’s
the natural selection bias right there; the patients come in
randomly.
The other selection bias is that we do not do Marfan patients, so
the entire Marfan subgroup was excluded, and that’s about 15% of
cases. We do not perform the procedure in patients we believe will
have<10-year life expectancy from their age.
An analysis probably should be done to take out that side. But
that is the actual selection algorithm right there.
Dr Hughes. Yes. I would say if there is institutional buy-in, I
would question why 3 of the surgeons don’t do it.
Dr Bavaria. That’s a good question. I can’t answer that.
Dr Hughes. Okay. We’ll move on.
Dr Bavaria. I think they’re a little younger and may not be as
self-secure.
Dr Hughes. Yeah, got it.
Although the postoperative outcomes as presented suggest no
adverse effects of the addition of antegrade stent graft deployment
to standard dissection repair, the results are unadjusted and do not
take into account potential differences in the risk profiles of the
groups.
For example, the incidence of preoperative renal failure was
nearly double in the standard versus stented group, and the inci-
dence of preoperative shock or performance of concomitant coro-
nary artery bypass grafting was not reported, all of which are
predictors of composite mortality or major morbidity following
proximal aortic replacement based on data from more than
45,000 patients in the Society of Thoracic Surgeons database,
which we recently published in Journal of The American College
of Cardiology.
Further, the International Registry of Acute Aortic Dissection
has previously published a risk model for type A dissection repair
that could be used to risk adjust the patient cohorts, or ideally, the
analysis could be repeated with a propensity-matched design that
would better account for any potential differences between the
groups. Please comment on that.
Dr Bavaria.Wewent through the univariate analysis of the pre-
operative risk factors, and there wasn’t anything that was below
0.05.
But I totally agree with you. The next iteration should be a
propensity-matched analysis, and I totally agree that we should
do a little bit more robust analysis of preoperative factors to
make sure that we are comparing apples to apples here, and I think
a propensity analysis is perfect.
At some point we are probably going to have to do a prospective
randomized study on this. I think the equipoise is satisfactory
enough to do that. That probably will require a multicenter trial.
Dr Hughes. That gets to my last question: Although the
decreased need for open reintervention is interesting, it seemed
somewhat less compelling in the absence of the survival benefit.
Do you have any thoughts on why you’re not seeing a survival
benefit at this point?
Dr Bavaria. That is a very good question. I do not know why
there is not a survival benefit. You might think there should be.
Some of this may be because there was a significant learning curve
with the original 10 or 15 cases. We had to do some interventions
because we were placing the stents too distally, and as Eric Roselliery c March 2014
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imal—we figured that out.
We basically cover the subclavian artery. We bring it as far
proximal as possible. We don’t cut out the graft like Eric does,
but we do bring them as far proximal as possible.
That was probably something that affected the mortality rate on
the stented side at the beginning of the series. I do not really know
the answer. We’ll see.
Dr Hughes.Well, again, congratulations, and I echo your senti-
ment. I think this would bewell suited to a multicenter randomized
trial.
Dr Bavaria. Thank you very much, Chad.
Dr Marc R. Moon (St Louis, Mo). Joe, does this have to be a
covered stent graft? Couldn’t you just put in a stent? Wouldn’t it
effectively do the same thing?
Dr Bavaria. One of the reasons why it works in these selected
patients is because many times there is a large fenestration in the
proximal descending aorta that we cannot get to.
So if you have a large fenestration in the proximal descending
aorta, then a pure stent would maybe not work as well. It would
theoretically work as well if there were not a large communication
in the proximal descending aorta. But if you have a large commu-
nication in the proximal descending aorta, then you need a fully
covered stent.
DrAlberto Pochettino (Rochester, Minn). I just want to make a
couple of comments, because I was involved in this study.
The first issue raised regarding patient selection is a good one,
and I want to emphasize that this was awork in progress. The first 8
to 10 patients were indeed what I would call a pilot project; most
were patients who definitely had malperfusion and needed some-
thing more than a standard operation. We were impressed with
how good the results were in those initial, intrinsically high-risk
patients.
What came down within the University of Pennsylvania was
that 1 of the surgeons—myself—went on to generalize the use
of this technique to all Debakey type I dissections, with the only
exclusion being collagen vascular disease. The remaining sur-
geons were not compelled to embark on a modification that makes
an operation that is intrinsically difficult even more difficult and
increases the circulatory arrest time by about 20 minutes, without
clear-cut, up-front evidence that it would be of benefit.
Ultimately, as the results improved, some of the other surgeons,
Bavaria being one of them, started using the antegrade stent
technique.
As we think back, the issue remains as to whether or not this
technique is worthwhile. I don’t as yet know the answer. I’ve
been impressed that the technique is safe and reproducible, with
equivalent results to the standard type A repair.
As we analyze the long-term outcomes most of the patients in
the 2 groups, aside from the early pilot project, are indeed similar
in presentation and early outcomes. I don’t remember seeing a
particular bias regarding the stented group being sicker or not as
sick compared with the other groups. Again, the early pilot project
was a little bit different.
Dr Anthony Estrera (Houston, Tex). Joe, nice job. The concept
is good. I do like the concept, and if the data of the Investigation of
Stent Grafts in Patients With Type B Aortic Dissection trial bearsThe Journal of Thoracic and Caout as Nienaber has presented most recently at 5 years is anything
to go by, you should see a difference as your data matures.
My question is related to spinal cord ischemia and paraplegia.
Although it wasn’t significant, the P value was .07. Because the
stent-graft is thrombosing-remodeling—all those relevant inter-
costals—what are your thoughts about paraplegia and was your
study powered enough to show a difference?
Dr Bavaria.We probably do not have enough data right now. I
have a slide I didn’t show that is not just the survival differences
between the 2 groups as far as the learning curve is concerned,
but also the entire morbidity and mortality profile in the learning
curve.
We had 5 spinal cord ischemic events, and all 4 of those were in
the first part of the series. And that’s why at the beginning we
didn’t know how long the stents should be, and now we’ve kind
of standardized that. But you’re right, it is an issue.
Dr Eric E. Roselli (Celevand, Ohio). Joe, great presentation.
Just 2 really quick questions.
Despite the fact that you show there was more malperfusion and
longer circulatory arrest times in your stented patients, there was
really no difference in mortality. Did you do any additional adjunc-
tive procedures like stenting any static occlusions of organs down-
stream at the same time in any of your patients?
Dr Bavaria. No, we did not. The only adjunct is that we are do-
ing more and more of these operations in the endo suite now, so
when we put a stent in, we’ll shoot a completion angiogram.
Dr Roselli. Great. I think that’s an important part of the pro-
cedure. A serendipitous finding in my series was that I think we
can treat these patients with malperfusion better using the hybrid
suite.
My second question concern folks who had persistent false
lumen perfusion in the stented area on follow-up. Have you done
an imaging analysis to see if they had persistent dissection in the
branch vessels of their arches? I suspect that may be a common
area where a persistent entry tear was filling the false lumen of
the aorta.
Dr Bavaria. I agree with that concept. I think the differential
between my technique—or our technique—and maybe even
your technique and Di Bartolomeo’s technique right behind you,
is that they’re doing a total arch, and they have a sewn-in graft
where there is no communication. In other words, there is no land-
ing zone in this dissected aorta.
We’re getting into the mid-70s pretty consistently; between
70% and 80% success. But we have 20% to 25% nonsuccess
compared with what Roberto is going to tell us, probably 10%
with a full elephant trunk graft that is made for this.
So I think you’re right. There are either left subclavian or type
1A endoleak situations that you can think about. We had more of
these in the early phase because we learned a lot and put them up
more proximally now.
Dr Moon. Hopefully you’ve decreased the pressure so much in
that false lumen that it’s not going to be a problem and dilate over
time like it would be if you didn’t have the stent in there.
Dr Bavaria. I agree. I think that differential between putting a
stent in antegrade under a hemiarch condition compared with a to-
tal arch with a designed E-Vita type of graft (JOTEC, Hechingen,
Germany), that does explain the differential, which is about 15%.rdiovascular Surgery c Volume 147, Number 3 949
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DDr Moon. How much contrast do you do on your completion
angiogram? What can you do?
Dr Bavaria. As little as possible.
Dr Moon. Fifteen for 30?
Dr Bavaria. Yes.
Dr Roselli. Mine is 12.5 cc, 15 for 25 with half-strength
contrast.
Dr Bavaria. Ten for 30 or something like that. Right at the end
of the stent so it doesn’t get hung up.
Dr Roberto Di Bartolomeo (Bologna, Italy). Joe, my compli-
ments on your presentation and your technique. What do you think
about our initial experience in type B acute aortic dissection with
impending rupture and/or visceral malperfusion to use the frozen
elephant trunk technique?
Dr Bavaria. For type B?950 The Journal of Thoracic and Cardiovascular SurgDr Di Bartolomeo. Yes, for type B acute dissection when there
is impending rupture or/and distal malperfusion.
Dr Bavaria. With the E-Vita?
Dr Di Bartolomeo. Yes.
Dr Bavaria. Yes, it makes sense.
Dr Di Bartolomeo. Seventy percent of patients have the acute
aortic dissection in the ascending aorta, and 22% start in the de-
scending aorta. With our operation, the frozen elephant trunk, us-
ing the E-Vita—or now the Thoraflex, the new device from
Vascutek (Renfrewshire, Scotland)—it’s possible to remove the
ascending aorta and aortic tissue in the same operation, also
reducing the risk of the type A aortic dissection. Is it a good
idea?
Dr Bavaria. I think that is going to be the topic of our next
research project. That’s a nice segue.ery c March 2014
